Results 131 to 140 of about 13,346 (214)
A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor
Biomarker ResearchOsteosarcoma is the commonest malignant bone tumour in children, with a poor prognosis due to limited treatment options. Antibody–drug conjugates (ADCs) offer targeted therapeutic potential but are limited by the low expression of specific antigens like ...
Jing Shan +14 more
doaj +1 more source
Aktive Immunisierung mit GD2-Peptidmimotopen und anti-Idiotypen zur Immuntherapie beim Neuroblastom [PDF]
, 2013 Das Neuroblastom ist der häufigste solide, extrakranielle Tumor des Kindesalters. Die schlechte Prognose von Patienten mit fortgeschrittener Erkrankung macht die Entwicklung neuer Therapiemodalitäten zu einem der wichtigsten Forschungsziele auf dem ...
Bleeke, Matthias
core
, 2010 Ganglioside GD2 is a cell surface glycosphingolipid. Targeting of GD2, i.e., by anti-GD2 mAb 3F8, is used clinically for cancer diagnosis, prognosis, and therapy.
Saragovi, H. Uri +13 more
core +1 more source
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source
Targeting NFκB signaling in GD2+ BCSCs
Aging, 2017 Nguyen, Khoa, Battula, V. Lokesh
openaire +2 more sources
Abstract Objectives Disialoganglioside 2 (GD2), overexpressed by cancers such as melanoma and neuroblastoma, is a tumor antigen for targeted therapy. The delivery of conventional IgG antibody technologies targeting GD2 is limited clinically by its co-expression on nerves that contributes to toxicity ...
Zachary T. Rosenkrans +9 more
openaire +2 more sources
Changes in the Metabolism of GD2-Specific Murine CAR-T Cells After Co-Culturing with Melanoma. [PDF]
Int J Mol SciBulygin A +11 more
europepmc +1 more source